Altre lingue Amoy Diagnostics Co., Ltd.

Azioni

300685

CNE1000034D3

Prezzo di chiusura Shenzhen S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
21,55 ^CNY	+2,13%		+2,13%	-1,96%

22/04	Amoy Diagnostics Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
15/04	Amoy Diagnostics Co., Ltd. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	22/04
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.	01/04
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index	11/12
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index	11/12
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23/10/23
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/07/23
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China	26/07/23
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023	16/05/23
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022	12/05/23
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/04/23
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022	17/04/23
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC	27/03/23
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC	27/03/23
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	14/02/23
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million.	13/02/23
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	03/01/23
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/10/22
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022.	10/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Amoy Diagnostics Co., Ltd.

Azioni

300685

CNE1000034D3

Altre lingue

Filtri